Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Upper Tract Urothelial Carcinoma Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

NCT04180371
View directory record Official record
Conditions
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Interventions
BT5528, Nivolumab
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Encinitas, California • Orange, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma

NCT01606345
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Valrubicin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

NCT06774131
View directory record Official record
Conditions
Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma
Interventions
UGN-104
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
25
States / cities
Homewood, Alabama • Chandler, Arizona • Queen Creek, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

NCT05775471
View directory record Official record
Conditions
Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Biopsy, Biospecimen Collection, Enfortumab Vedotin, MR Urography, Nephroureterectomy, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

NCT03504163
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab (MK-3475), Bacillus Calmette-Guérin (BCG)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting Phase 2 Interventional

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer

NCT06356155
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Enfortumab vedotin, Pembrolizumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

NCT04628767
View directory record Official record
Conditions
Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Pegfilgrastim, Therapeutic Conventional Surgery, Vinblastine Sulfate
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
258
States / cities
Kingman, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 198 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

NCT03693612
View directory record Official record
Conditions
Neoplasms
Interventions
feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting No phase listed Observational

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

NCT05874921
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Interventions
Jelmyto (mitomycin) for pyelocalyceal solution
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
22
States / cities
Santa Monica, California • Gainesville, Florida • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting Phase 2 Interventional

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

NCT06822010
View directory record Official record
Conditions
Urinary Bladder Cancer, Upper Tract Urothelial Cancer, Urothelial Cancer
Interventions
Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel)
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1 Interventional

Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)

NCT03617003
View directory record Official record
Conditions
Upper Tract Urothelial Carcinoma
Interventions
WST11 mediated vascular targeted phototherapy (VTP), Endoscopy
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jul 23, 2026, 2:10 PM EDT
Terminated Phase 2 Interventional Results available

Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)

NCT01663285
View directory record Official record
Conditions
Urothelial Cancer, Bladder Cancer
Interventions
Neoadjuvant Cisplatin and Gemcitabine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting Not applicable Interventional

A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial

NCT06040762
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Upper Tract Urothelial Carcinoma, Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Best Practice, Exercise Intervention, App-Based Intervention, Interview, Wearable Activity Tracker, Physical Performance Testing, Questionnaire Administration
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study

NCT02793128
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Interventions
UGN-101 instillations
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Jul 23, 2026, 2:10 PM EDT
Not yet recruiting Phase 2 Interventional

Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy

NCT03345134
View directory record Official record
Conditions
High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma, Endoscopic Surgical Procedure, Transitional Epithelial Cells
Interventions
MK-3475 and BCG
Drug
Lead sponsor
Shaheen Alanee
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting Not applicable Interventional

Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma

NCT06262516
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Nephroureterectomy, Lymph Node Dissection
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Gainesville, Florida • Springfield, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting No phase listed Observational

Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer

NCT06310759
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Not listed
Lead sponsor
Tampere University Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jul 23, 2026, 2:10 PM EDT